Quest Diagnostics Inc (DGX)

DGX on New York Consolidated

75.58USD
1 Apr 2015
Change (% chg)

$-1.27 (-1.65%)
Prev Close
$76.85
Open
$76.86
Day's High
$76.86
Day's Low
$75.27
Volume
3,215,304
Avg. Vol
1,577,525
52-wk High
$78.33
52-wk Low
$54.90

DGX

Chart for DGX

About

Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. The Company’s operations are organized in two business groups, such as diagnostics information services and diagnostic solutions.... (more)

Overall

Beta: 0.63
Market Cap(Mil.): $11,090.32
Shares Outstanding(Mil.): 144.31
Dividend: 0.38
Yield (%): 1.98

Financials

  DGX Industry Sector
P/E (TTM): 20.30 24.63 41.18
EPS (TTM): 3.79 -- --
ROI: 7.37 7.10 16.23
ROE: 13.31 21.27 17.07
Search Stocks

Quintiles, Quest to combine clinical trial lab operations

- Medical tests maker Quest Diagnostics Inc and contract research company Quintiles Transnational Holdings Inc said they were combining their clinical trial laboratory operations in a joint venture.

31 Mar 2015

UPDATE 1-Quintiles, Quest to combine clinical trial lab operations

March 31 - Medical tests maker Quest Diagnostics Inc and contract research company Quintiles Transnational Holdings Inc said they were combining their clinical trial laboratory operations in a joint venture.

31 Mar 2015

Fitch Rates Quest Diagnostics' Bond Offering 'BBB'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, March 05 (Fitch) Fitch Ratings has assigned a 'BBB' rating to the $1.2 billion bond offering by Quest Diagnostics Inc. (Quest; NYSE: DGX). The Rating Outlook is Stable. A full list of ratings follows at the end of this release. Fitch expects the bond proceeds, as well as internal liquidity sources, to be used to repay up to $1,275 million of outstanding debt and associated fees during 2015, including: --$500 million of 5.45

05 Mar 2015

Myriad, Quest settle dispute over genetic cancer test

- Quest Diagnostics and Myriad Genetics have settled their patent dispute over genetic testing technology used to detect breast cancer.

09 Feb 2015

Quest in broad deal with CDC for hepatitis analysis

- Laboratory testing company Quest Diagnostics Inc said on Tuesday it had signed a $520,000 agreement with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment of four strains of viral hepatitis.

27 Jan 2015

Quest says content with diagnostics, does not need CRO

- The chief executive of Quest Diagnostics Inc said his company will stick to its core business of diagnostic testing and is not interested in acquiring a contract research organization (CRO), despite such a planned move by rival diagnostics firm LabCorp .

05 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks